Abstract: A system for the therapeutic treatment of joints comprising a composite material comprising a biodegradable polymer matrix and a plurality of piezoelectric particles adapted to generate local electric charges in response to an external stimulation made by means of ultrasound, said plurality of piezoelectric particles being dispersed in the matrix. The composite material also comprises a plurality of stamina cells dispersed in the biodegradable polymer matrix and a plurality of carbon-based particles. The system also comprises a releasing device, arranged to deposit the composite material in a joint cavity at predetermined areas of the cartilage, and a stimulator device arranged to emit ultrasound at a predetermined frequency, a predetermined intensity and for a predetermined time of application, in such a way that, when the device is located near a joint wherein the composite material has been deposited, said ultrasound stimulate the plurality of piezoelectric particles.

Abstract: A device for external orthopedic fixations, which has one or more frames which have a substantially and/or partially annular shape and are suitable for being arranged around a limb to surround it at least partially, wherein one or more rods are fixed to a frame by means of a locking mechanism is provided. The device has two jaws which, when closed, tighten the locking mechanism to a portion of the frame by exerting a prevalently axial force, wherein the jaws are closed by means of a cam mechanism suitable for being actuated by rotating a lever pivoted to a first jaw and provided with one or more cam surfaces cooperating with a surface of the second jaw.

Abstract: The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ri is selected from an SCN— group or is an RCONH— group; in particular, where Ri=RCONH, R is selected from an aromatic benzene ring substituted with an SCN— group in the ortho, meta or para position, according to the following formula: SCN— or R is a C1-C4 alkyl chain, substituted with an SCN— group; n can be equal to 0 or else 1. The invention also relates to the use of such compounds for the treatment of osteoporosis and in general of bone pathologies characterized by a progressive loss of bone mass, for example rheumatoid arthritis, hyperparathyroidism or bone tumor metastases.

Abstract: The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ri is selected from an SCN— group or is an RCONH— group; in particular, where Ri=RCONH, R is selected from an aromatic benzene ring substituted with an SCN— group in the ortho, meta or para position, according to the following formula: SCN— or R is a C1-C4 alkyl chain, substituted with an SCN— group; n can be equal to 0 or else 1.

Abstract: The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. The single-chain variable fragment is able to recognize and specifically and selectively bind the epitope of the extracellular domain of CD99 human protein expressed on Ewing sarcoma cells. The fragment can thus be used for the diagnosis and 10 treatment of Ewing sarcoma.

Abstract: Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments.

Abstract: A method of treatment of connective tissue includes the steps of providing a biological tissue or organ, coating the tissue or organ with an enzymatic solution capable of phagocytizing at least partly fibroblasts, macrophages, mast cells and other cells responsible for immune and rejection reactions in homologous and heterologous transplantations. The biological tissue or organ, after the treatment with the enzymatic solution is irradiated with ionizing electromagnetic radiations in order to obtain an acellular tissue which maintains its own extracellular matrix unchanged. Preferably, such radiations are gamma radiations having a frequency between 1019 and 1022 Hz, beta radiations or mixtures thereof.

Abstract: The present invention refers to a porous composite material, wherein at least one interdispersed biopolymer is present, with a calcium-phosphate mineral component comprising from 50 w/% to 95 w/% of ?-tricalcium phosphate (?-TCP, ?-Ca3(PO4)2) and from 5 w/% to 50 w/% of octacalcium phosphate (OCP, Ca8H2(PO4)6—5H2O), to the total weight of the mineral component. Such combination of ?-TCP and OCP allows an in vivo faster resorption rate and thereby a faster formation of new bone tissue having a low cristallinity mineral component with nanocrystal structure, features very similar to those of biological apatites. This porous composite material may find application as bone and/or osteal-chart ilagineous substitute (scaffold) and in producing tissue engineering devices.

Abstract: Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments.